The pedunculopontine nucleus (PPN) is a potential target for gait disorders. We report 4 cases of bilateral PPN stimulation in progressive supranuclear palsy (PSP) patients with short-term (6 months) and long-term (18 months) follow-ups. Patients with PSP who had gait disturbances, but were able to walk with or without assistance, were selected. The patients' median age was 64 years and the disease duration 3 years. Bilateral PPN deep brain stimulation (DBS) was performed. The pacemaker was programmed using a bipolar mode and lower frequencies (20-45 Hz). The PSP rating scores (PSPRS) and their gait subscores (No. 25, 26, 27 and 28) along with PSP staging scores were used as primary end points. The total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS III and the 39-item Parkinson's Disease Questionnaire were considered as secondary end points. Video recordings of the gaits were performed before surgery and at the 6- and 18-month follow-ups. These were retrospectively reviewed by a blinded neurologist for the primary end points. At the 6- and 18-month follow-ups, the median change in PSPRS was from 33 (baseline) to 37.5 and 47, respectively. Similarly, the PSP staging changed from 3 to 2.5 and 3.5, item 25 from 1.5 to 2 and 3.5, item 26 from 2.5 to 2 and 3.5, item 27 from 3.5 to 3 and 3.5 and item 28 from 1.5 to 1.5 and 3. Two patients in the study with the PSP-parkinsonism phenotype experienced improvement in their gait until the last follow-up. Bilateral PPN DBS can be safely performed in PSP patients despite mid-brain atrophy.

Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T: Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566-1576.
Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
Schofield EC, Hodges JR, Macdonald V, Cordato NJ, Kril JJ, Halliday GM: Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord 2011;26:256-263.
Morris HR, Wood NW, Lees AJ: Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgrad Med J 1999;75:579-584.
Eidelberg E, Walden JG, Nguyen LH: Locomotor control in macaque monkeys. Brain 1981;104:647-663.
Hamani C, Moro E, Lozano AM: The pedunculopontine nucleus as a target for deep brain stimulation. J Neural Transm 2011;118:1461-1468.
Mesulam MM, Geula C, Bothwell MA, Hersh LB: Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. J Comp Neurol 1989;283:611-633.
Jenkinson N, Nandi D, Muthusamy K, Ray NJ, Gregory R, Stein JF, Aziz TZ: Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord 2009;24:319-328.
Pahapill PA, Lozano AM: The pedunculopontine nucleus and Parkinson's disease. Brain 2000;123:1767-1783.
Hamani C, Stone S, Laxton A, Lozano AM: The pedunculopontine nucleus and movement disorders: anatomy and the role for deep brain stimulation. Parkinsonism Relat Disord 2007;13(suppl 3):S276-S280.
Plaha P, Gill SS: Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport 2005;16:1883-1887.
Stefani A, Lozano AM, Peppe A, Stanzione P, Galati S, Tropepi D, Pierantozzi M, Brusa L, Scarnati E, Mazzone P: Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007;130:1596-1607.
Pereira EA, Muthusamy KA, De Pennington N, Joint CA, Aziz TZ: Deep brain stimulation of the pedunculopontine nucleus in Parkinson's disease. Preliminary experience at Oxford. Br J Neurosurg 2008;22(suppl 1):S41-S44.
Ferraye MU, Debu B, Fraix V, Goetz L, Ardouin C, Yelnik J, Henry-Lagrange C, Seigneuret E, Piallat B, Krack P, Le Bas JF, Benabid AL, Chabardes S, Pollak P: Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 2010;133:205-214.
Moro E, Hamani C, Poon YY, Al-Khairallah T, Dostrovsky JO, Hutchison WD, Lozano AM: Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain 2010;133:215-224.
Mazzone P, Lozano A, Stanzione P, Galati S, Scarnati E, Peppe A, Stefani A: Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. Neuroreport 2005;16:1877-1881.
Ostrem JL, Christine CW, Glass GA, Schrock LE, Starr PA: Pedunculopontine nucleus deep brain stimulation in a patient with primary progressive freezing gait disorder. Stereotact Funct Neurosurg 2010;88:51-55.
Wilcox RA, Cole MH, Wong D, Coyne T, Silburn P, Kerr G: Pedunculopontine nucleus deep brain stimulation produces sustained improvement in primary progressive freezing of gait. J Neurol Neurosurg Psychiatry 2011;82:1256-1259.
Brusa L, Iani C, Ceravolo R, Galati S, Moschella V, Marzetti F, Stanzione P, Stefani A: Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits. Mov Disord 2009;24:2020-2022.
Hazrati LN, Wong JC, Hamani C, Lozano AM, Poon YY, Dostrovsky JO, Hutchison WD, Zadikoff C, Moro E: Clinicopathological study in progressive supranuclear palsy with pedunculopontine stimulation. Mov Disord 2012;27:1304-1307.
Takahashi R, Ishii K, Kakigi T, Yokoyama K, Mori E, Murakami T: Brain alterations and mini-mental state examination in patients with progressive supranuclear palsy: voxel-based investigations using 18F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging. Dement Geriatr Cogn Dis Extra 2011;1:381-392.
Mungas D: In-office mental status testing: a practical guide. Geriatrics 1991;46:54-58, 63, 66.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE: Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
Zrinzo L, Zrinzo LV, Tisch S, Limousin PD, Yousry TA, Afshar F, Hariz MI: Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. Brain 2008;131:1588-1598.
Golbe LI, Ohman-Strickland PA: A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552-1565.
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease: The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
Hobson P, Holden A, Meara J: Measuring the impact of Parkinson's disease with the Parkinson's disease quality of life questionnaire. Age Ageing 1999;28:341-346.
Goetz CG, LeWitt PA, Weidenman M: Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 2003;18:1455-1458.
Geula C, Schatz CR, Mesulam MM: Differential localization of NADPH-diaphorase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum and brainstem in the rat, monkey, baboon and human. Neuroscience 1993;54:461-476.
Mesulam MM, Mufson EJ, Wainer BH, Levey AI: Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983;10:1185-1201.
Afshar F, Watkins ES, Yap JC: Stereotaxic Atlas of the Human Brainstem and Cerebellar Nuclei. A Variability Study. New York, Raven Press, 1978.
Williams DR, Lees AJ: Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-279.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.